Investment Rating - The report maintains an "Overweight" (OW) rating for the healthcare sector, particularly favoring innovative drug-related companies such as Akeso and Innovent Biologics [17][20]. Core Insights - The Hang Seng Healthcare Index (HSHCI) has shown resilience, recovering 32% from its lows after the announcement of tariffs, outperforming the Hang Seng Index (HSI) which only recovered 19% [3]. - The report highlights the increasing confidence of investors in China's innovative drug R&D capabilities, supported by significant out-licensing deals to developed countries [3][4]. - The HSHCI is expected to potentially reach or exceed its 2023 and 2022 highs in the coming years, driven by strong sales growth and ongoing out-licensing deals [4][8]. Summary by Sections Historical Context - Recent news, including a ruling against President Trump's tariff authority, positively impacted the HSHCI, which rose by 4.2% on May 29, 2025 [2]. - The HSHCI has surpassed its highest point in 2024 but remains below its 2023 peak of approximately 4,400 and 2022 peak of around 4,600 [2]. Market Performance - The HSHCI's performance has been bolstered by key deals, such as the 3Sbio-Pfizer agreement worth US$1.25 billion, and clinical data presentations from China at ASCO'25 [3]. - The report notes that the number and value of out-licensing deals have reached record levels in 2023 and 2024, continuing into 2025 [4]. Future Outlook - The report anticipates that the current momentum in the China healthcare sector will drive the HSHCI higher, with expectations of reaching its highest point from 2023 [8]. - Concerns about potential corrections post-ASCO are downplayed, as there is strong interest from overseas investors in China's innovative drug companies [9].

Investment Rating - The report maintains an "Overweight" (OW) rating for several companies including Genscript Biotech, Innovent Biologics, Kingdee International, and Zhongsheng Group Holdings [32][46][50][53]. Core Insights - The A-share SMid indices, particularly the micro-cap CSI2000, have outperformed the CSI300 year-to-date (YTD), with CSI2000 rising by 12.9% compared to CSI300's 0.2% [2][3]. - High-beta micro-caps have benefited from robust trading volumes and less national team ownership, leading to increased retail trading interest [3][4]. - The outlook for 2Q25 suggests a range-bound trading environment for MXCN, with potential upside driven by trade negotiations and possible reforms in China [4][8]. Summary by Sections Market Performance - The micro-cap CSI2000 has outperformed other indices, with H shares rising by 15% to 18% in USD terms compared to the flat performance of onshore indices [2][3]. - The consensus EPS for SMids has faced significant downgrades, with declines of 13% and 17% for CSI500 and CSI1000 respectively [8][16]. Sector Analysis - Defensive sectors such as Healthcare, Utilities, and Consumer Staples have performed well, while Real Estate and IT lagged behind [8][25]. - Healthcare and IT remain preferred themes, with expectations for biotech shares to benefit from improved policy outlooks and AI adoption in IT [8][25]. Company-Specific Insights - Kingdee International has seen a 51% increase in shares YTD, supported by AI adoption [10]. - Innovent's shares have surged by 98% YTD, driven by strong product sales and potential for significant revenue growth from new drugs [10]. - Genscript is expected to achieve a 45% CAGR from 2024 to 2026, with profitability anticipated in 2026 [10].

Investment Rating - The report assigns a "Buy" rating to Innovent Biologics with a revised 12-month price target of HK$74.95, reflecting an upside potential of 15.2% from the current price of HK$65.05 [15][9]. Core Insights - Innovent Biologics has shown encouraging survival benefits for its drug IBI363 in various cancer indications, particularly in IO-treated squamous and adeno NSCLC, with improved overall response rate (ORR) and progression-free survival (PFS) data compared to previous reports [1][2][12]. - The risk-adjusted sales forecast for IBI363 has been raised to US$3.2 billion by 2035, up from US$1.4 billion, due to the addition of 2L adeno NSCLC and an increase in the probability of success (POS) for other indications [1][9]. - The report highlights the importance of randomized controlled trials (RCT) to further validate the long-term benefits of IBI363, especially in the context of its mechanism of action that enhances the immune environment [7][12]. Summary by Sections Clinical Data - The updated phase 1 data for IBI363 indicates a median PFS of 9.3 months for the high-dose cohort, an increase from 7.3 months previously reported, and a median overall survival (mOS) of 15.3 months, suggesting a strong conversion from PFS to OS [2][7]. - In adeno NSCLC, the median PFS was shorter at 5.6 months, but the overall survival data remains competitive, indicating potential lasting benefits post-disease progression [3][7]. Market Position and Valuation - Innovent Biologics is positioned as a leading biopharma company in China with a robust pipeline of over 30 assets, including the leading PD-1 inhibitor sintilimab [12]. - The report emphasizes that Innovent is undervalued at current levels, with a high market-implied weighted average cost of capital (WACC) that does not fully reflect its strong revenue potential and pipeline [12]. Future Outlook - The ongoing phase 1b/2 trial for IBI363 in combination with chemotherapy in the first-line setting is expected to generate further discussions regarding its competitive safety profile and efficacy [8][12]. - The report anticipates that the company will maintain its leading position in the biotech sector in China, supported by strong commercialization capabilities and collaborations with global partners [12].

Investment Rating - The report does not explicitly provide an investment rating for the China drug industry but discusses potential impacts of US drug pricing changes on the sector [5]. Core Insights - The report highlights significant uncertainty regarding the Trump administration's plans for US drug pricing, which could affect the Chinese drug industry in various ways [5]. - Changes in US drug pricing could hinder the Chinese drug industry's international expansion due to a perceived smaller US market, but may also create opportunities for Chinese innovative drugs to be licensed out due to R&D cost advantages [5]. - The report notes that Chinese CRO/CDMO companies may face mixed impacts; reduced R&D expenses from US clients could negatively affect them, while increased outsourcing demand could arise as companies seek cost-saving measures [5]. Summary by Sections Impact of US Drug Pricing Changes - The report discusses the uncertainty surrounding the implementation of a "most favored nation" pricing model and its potential opposition in the US [5]. - It emphasizes that the actual impact on the Chinese drug industry remains unclear due to various factors, including whether Medicare or Medicaid pricing will be affected [5]. Opportunities and Challenges for Chinese Companies - If US drug prices decrease, it could limit the Chinese drug industry's ability to expand internationally [5]. - Conversely, innovative drugs from China may have better licensing opportunities due to their potential R&D cost and speed advantages [5]. - For Chinese CRO/CDMO companies, the report suggests that while some clients may cut R&D expenses, the overall demand for outsourcing could increase [5].

Investment Rating - The report raises the Southbound flow forecast from US$75 billion to US$110 billion for 2025, indicating a positive outlook for Southbound investments [7][35][41]. Core Insights - Emerging markets in Asia, excluding China, experienced strong foreign institutional investor (FII) inflows of US$2.8 billion week-over-week, primarily driven by Taiwan [6][44]. - In April, Korea led the regional foreign selling, while domestic institutional flows in India remained robust [7][8]. - Global equity mutual funds saw inflows of US$8 billion week-over-week, with significant outflows from US funds [6][10]. Summary by Sections Foreign Institutional Investor (FII) Flows - EM Asia ex-China markets saw FII buying of US$2.8 billion week-over-week, led by Taiwan (+US$1.7 billion) [6][44]. - Southbound flows recorded US$0.2 billion this week, totaling US$78 billion year-to-date [6][35]. - In April, Korea experienced significant FII selling, while India saw strong domestic institutional inflows [7][8]. Mutual Fund Performance - The largest 350 EM and Asian mutual funds rebounded, posting average returns of 1-4% year-to-date, with EM funds outperforming Asia funds by 3 percentage points [7][8]. - Only 20-40% of the largest Asian/EM funds outperformed their benchmarks in April, below the 10-year average of 55-65% [11][12]. Southbound Flows - Southbound flows have made the strongest start of a year in history, with US$78 billion year-to-date [7][35]. - The report highlights a significant increase in Southbound ownership in the Hong Kong market, indicating growing interest from mainland investors [37][41]. - The top buying stocks in Southbound flows included Meituan Dianping and Akeso, while Tencent and Alibaba saw significant selling [67][71].

Investment Rating - The report maintains a "BUY" rating for Innovent Biologics, indicating a potential return of over 15% over the next 12 months [16]. Core Insights - Innovent Biologics is entering a phase of sustainable profitability, having achieved a full-year non-IFRS net profit of RMB332 million in FY24, driven by strong product revenue growth and one-off license fee income [8]. - The target price has been revised upwards from HK$57.67 to HK$61.71, reflecting a 33.6% upside potential from the current price of HK$46.20 [3][8]. - The company is advancing its next-generation immuno-oncology (IO) therapies and antibody-drug conjugates (ADCs), with significant clinical programs underway [8]. Financial Summary - Revenue is projected to grow from RMB6,206 million in FY23 to RMB11,356 million in FY25, representing a year-on-year growth of 51.8% [2][13]. - Net profit is expected to turn positive in FY25, reaching RMB445.7 million, with EPS projected at RMB0.27 [2][11]. - R&D expenses are forecasted to remain stable, while gross profit margin is expected to expand to 84.9% in FY24 from 82.8% in FY23 [2][8]. Share Performance - The market capitalization of Innovent Biologics is approximately HK$75.68 billion, with a 52-week high of HK$51.15 and a low of HK$30.00 [3][4]. - The stock has shown strong performance, with a 1-month absolute return of 14.2% and a 3-month return of 29.8% [5]. Pipeline and Growth Potential - Innovent has a robust pipeline with over 10 ADC clinical programs and is focusing on combination trials with its next-generation IO therapy, IBI363 [8]. - The company aims to initiate multiple Phase 3 trials by 2030, targeting global markets with its innovative therapies [8].

Core Insights - Innovent achieved historic milestones in 2024, with Non-IFRS net profit of RMB 331.6 million and Non-IFRS EBITDA of RMB 411.6 million, marking the first positive results in these metrics [5] - Total revenue reached RMB 9,421.9 million, a year-over-year growth of 51.8%, with product sales revenue growing by 43.6% to RMB 8,227.9 million [5] - The company aims for RMB 20 billion in product revenue by 2027 and plans to advance five pipeline assets to global MRCT Phase 3 by 2030 [2][9] Financial Performance - Non-IFRS profit and EBITDA turned positive for the first time, indicating improved financial health [5] - Gross profit margin increased to 84.9%, up by 2.1 percentage points year-over-year [5] - Selling, General and Administrative (S,G&A) expenses ratio decreased to 50.9%, down by 7.1 percentage points year-over-year [5] Product Development and Pipeline - Innovent expanded its product portfolio to 15 approved products and plans six new product launches in 2025 [5][9] - Key pipeline assets include Dovbleron®, Limertinib, and Jaypirca®, targeting oncology and chronic diseases [5] - The company is advancing multiple next-generation programs in oncology and autoimmune diseases, with promising Phase 1 results reported [9] Strategic Goals and Partnerships - Innovent is focused on becoming a premier global biopharmaceutical company, emphasizing sustainable growth and innovation [2][9] - The company has established partnerships with over 30 global healthcare companies, enhancing its research and development capabilities [10] - Innovent's commitment to ESG practices is reflected in its 'AAA' rating in MSCI ESG rankings and various community support initiatives [9][10]

Core Insights - Ascentage Pharma's drug olverembatinib has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with low-intensity chemotherapy [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies for unmet medical needs, particularly in hematological malignancies [10][11] - The company is listed on both the Hong Kong Stock Exchange and Nasdaq, indicating its global presence and investment appeal [10] Drug Development and Approval - Olverembatinib is the first third-generation BCR-ABL inhibitor approved in China, with prior approvals for chronic-phase chronic myeloid leukemia (CML-CP) and gastrointestinal stromal tumors [5][12] - The drug has been included in the China National Reimbursement Drug List, enhancing its accessibility to patients [5][12] - A global Phase III study has been cleared for olverembatinib in combination with chemotherapy, positioning it to potentially be the first TKI approved for first-line treatment of Ph+ ALL in China [6] Clinical Significance - The incidence rate of ALL in China is approximately 0.69 per 100,000, with Ph+ ALL representing 20%-30% of adult cases, highlighting a significant unmet medical need [4] - Prior to TKIs, the five-year overall survival rate for Ph+ ALL patients treated with chemotherapy was below 20%, underscoring the importance of new treatment options [4] Regulatory and Market Impact - BTDs are granted to innovative drugs that address serious conditions with no existing treatment, allowing for prioritized development and review processes [3] - The recognition of olverembatinib's clinical value by regulatory authorities is expected to accelerate its development and availability to patients [7]